111 (NASDAQ:YI) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• 111 (NASDAQ:YI) received a "Sell (D-)" rating from Weiss Ratings, indicating negative sentiment towards its stock performance.
• Institutional investors have been actively adjusting their holdings in 111, with JPMorgan Chase & Co. increasing its stake by 43,619.9% in a recent quarter.
• The company's latest quarterly earnings reported a loss of ($0.20) EPS despite having significant revenue of $486.35 million.

Weiss Ratings reaffirmed their sell (d-) rating on shares of 111 (NASDAQ:YI - Free Report) in a report published on Thursday morning,Weiss Ratings reports.

111 Stock Up 2.1%

NASDAQ YI traded up $0.15 on Thursday, reaching $6.90. The company had a trading volume of 7,186 shares, compared to its average volume of 11,284. The stock has a market capitalization of $59.60 million, a PE ratio of -10.77 and a beta of 0.43. The firm's 50 day moving average price is $7.33 and its 200 day moving average price is $7.83. 111 has a 12 month low of $4.14 and a 12 month high of $11.90.

111 (NASDAQ:YI - Get Free Report) last issued its quarterly earnings results on Thursday, June 19th. The company reported ($0.20) earnings per share for the quarter. The firm had revenue of $486.35 million during the quarter.

Institutional Investors Weigh In On 111

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after acquiring an additional 305,339 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of 111 during the 1st quarter worth approximately $92,000. Finally, Deuterium Capital Management LLC purchased a new position in 111 in the 1st quarter valued at approximately $81,000. 21.32% of the stock is owned by hedge funds and other institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.